-
ECONOMIC AND CLINICAL OUTCOMES OF CELL-BASED VERSUS EGG-BASED INFLUENZA VACCINES IN U.S. PEDIATRIC AND ADULT POPULATIONS: A MODELING STUDY
Feb 25, 2026, 14:43 PM -
VALUE-BASED DECISION BOUNDARIES ANALYSIS (VB-DBA): A NOVEL METHOD OF INTEGRATING NETWORK META-ANALYSIS AND COST-EFFECTIVENESS MODELLING TO ESTIMATE PRICING THRESHOLDS BASED ON TARGET PRODUCT PROFILES
Feb 25, 2026, 14:43 PM -
HOW INDIVIDUALS CHOOSE MEDICATIONS: A DISCRETE CHOICE EXPERIMENT TO UNDERSTAND MANAGEMENT OF EYE ALLERGY RX TO OTC TREATMENT DECISIONS
Feb 25, 2026, 14:43 PM -
INCLUSION OF PATIENT-REPORTED OUTCOME MEASURES FOR PEDIATRIC VERSUS ADULT POPULATIONS IN FDA BIOLOGICAL AND NOVEL DRUG THERAPY APPROVALS FROM 2021-2025
Feb 25, 2026, 14:43 PM -
VALIDATING PRIMARY AND SECONDARY HEALTHCARE RESOURCE USE AND COSTS ESTIMATES IN OMOP-MAPPED VS SOURCE CPRD-HES DATA IN THE UK
Feb 25, 2026, 14:43 PM -
COMPARISON OF DAILY VS WEEKLY ADMINISTRATION FORMATS OF THE GLYCOGEN STORAGE DISEASE FUNCTIONAL ASSESSMENT DIARY (GSD FAD)
Feb 25, 2026, 14:43 PM -
ELEVATE GEN-AI FRAMEWORK-BASED INTERIM EVALUATION OF A GENAI-ENABLED PLATFORM FOR LITERATURE SCREENING OF A CLASS II MEDICAL DEVICE
Feb 25, 2026, 14:43 PM -
PRESERVING VISION AND PRODUCTIVITY: THE SOCIAL IMPACT OF INNOVATIVE DME THERAPY IN CHILE (2017-2032)
Feb 25, 2026, 14:43 PM -
COST-EFFECTIVENESS OF FITUSIRAN PROPHYLAXIS VERSUS FACTOR VIII ON-DEMAND OR PROPHYLACTIC THERAPY FOR HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Feb 25, 2026, 14:43 PM -
PATIENT DEMOGRAPHICS AND BASELINE CLINICAL CHARACTERISTICS IN GASTROESOPHAGEAL REFLUX DISEASE BY VONOPRAZAN TREATMENT DURATION: RESULTS FROM A POST-HOC ANALYSIS OF THE VIEW STUDY
Feb 25, 2026, 14:43 PM -
VIRTUAL REALITY AS AN ADJUNCTIVE TREATMENT TO OPIOID THERAPY IN PAIN MANAGEMENT AND IMPLICATIONS FOR ADDRESSING THE U.S. OPIOID EPIDEMIC
Feb 25, 2026, 14:43 PM -
TYPE 2 COMORBIDITIES IN PATIENTS INITIATING DUPILUMAB FOR ASTHMA: REAL-WORLD EVIDENCE FROM A NATIONAL US DATABASE
Feb 25, 2026, 14:43 PM -
GENAI FOR NEXT-GENERATION JCA WORKFLOWS: AUTOMATING EVIDENCE GENERATION WHILE ENSURING TRANSPARENT, TRACEABLE EU-HTA SUBMISSIONS
Feb 25, 2026, 14:43 PM -
COST-EFFECTIVE CKD SCREENING FOR ADULTS OVER 55 ADDRESSES MEDICAID POLICY MISALIGNMENT
Feb 25, 2026, 14:43 PM -
THE IMPACT OF MEDICATION ADHERENCE ON REAL-WORLD CLINICAL AND ECONOMIC OUTCOMES: A SCOPING REVIEW OF REAL-WORLD EVIDENCE
Feb 25, 2026, 14:43 PM -
IMPLEMENTATION OF EMBEDDED QUALITATIVE INTERVIEWS IN CLINICAL TRIALS: INSIGHTS FROM THE LITERATURE
Feb 25, 2026, 14:43 PM -
AN EXPLAINABLE MACHINE LEARNING ANALYSIS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) USE AND OPIOID-RELATED DIAGNOSIS RISK AMONG ADULT MEDICAID BENEFICIARIES
Feb 25, 2026, 14:43 PM -
EXPEDITED REGULATORY PATHWAYS AND REIMBURSEMENT DECISIONS FOR INNOVATIVE CANCER DRUGS IN CHINA
Feb 25, 2026, 14:43 PM -
REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) CAPTURES A 2025 STANDARD-OF-CARE (SOC) SHIFT DRIVEN BY ANTIBODY-DRUG CONJUGATES (ADCS) IN UROTHELIAL CARCINOMA (UC): IMPLICATIONS FOR HEALTH TECHNOLOGY ASSESSMENTS (HTAS)
Feb 25, 2026, 14:43 PM -
AUTOMATING MODEL PARAMETERISATION FOR HEALTH ECONOMIC MODELS: VALIDATION OF A GEN-AI RAG PIPELINE
Feb 25, 2026, 14:43 PM
